• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Change of Nominated Advisor

by admin | Jun 21, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

It is with great sadness that Scancell announces the death of former Chairman John Chiplin

by admin | Jun 20, 2024 | Latest News

It is with great sadness that Scancell announces the death of former Chairman John Chiplin John died on Tuesday after a valiant fight with Motor Neurone Disease. He faced this final challenge with great courage and his usual good humour, and his last years were spent...

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer

by admin | Jun 18, 2024 | Interviews, Latest News, Media Coverage, Modi-1, SCIB1

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer Scancell’s Chief Executive Officer, Lindy Durrant, recently sat down with Sarah Lowther from focusIR. During the interview Lindy highlights Scancell’s innovative...

Scancell Signs Agreement with Major International Biotechnology Company to Evaluate an Antibody in the Glymab® Portfolio

by admin | Jun 12, 2024 | GlyMab, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024

by chantal | Jun 11, 2024 | Modi-1, SCIB1, Vaccines

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma Samantha Paston, Heather Shaw, Poulam Patel, Miranda...

Recent Posts

  • Form F-4 (October 2026)
  • Preliminary Results for the year ended 30 April 2026
  • Atlantic crossing transforms outlook
  • Notice of General Meeting October 2026
  • Form of Proxy

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy